Circulation Research · 1961 · 81 citations · 14 references
MedicineCardiologyPharmacologyExperimental PharmacologyNeuropharmacologyPharmacodynamicsCardiac MedicationsCardiac PharmacotherapyCardiovascular PharmacodynamicsCardiovascular PharmacologyHemodynamic PharmacologyAdrenergic Receptor AntagonistsBeta-adrenergic Receptor PharmacodynamicsCardiovascular Drug PharmacologyCatecholamine InotropesCompetitive Receptor AntagonismHeart RatePharmacodynamics Of Cardiovascular DrugsPulmonary Arterial Pressure
The cardiac action of large doses of methoxamine and its antagonistic action to epinephrine were studied, using a dog heart-lung preparation. In doses of 4 mg. and above, methoxamine showed a marked negative inotropic action, while it produced only a slight decrease in the heart rate. Pretreatment of animals with 0.1 mg./Kg. of reserpine did not modify the inotropic action, but the decrease in the heart rate disappeared. Simultaneous with these changes, a decrease in the coronary flow and a rise of the pulmonary arterial pressure were observed. Methoxamine in doses of 1 mg. and more abolished both the positive inotropic and the positive chronotropic actions of epinephrine. The negative inotropic action of methoxamine was ascribed to a nonspecific, as yet undetermined mechanism, and the antagonistic action was ascribed to the competitive antagonism at the receptor site (thus methoxamine may be looked upon as a blocking agent of adrenergic β receptor). The weak negative chronotropic action was taken to be an expression of the blockade of the humoral effects of the intrinsic sympathomimetic amines.
14
A STUDY OF THE ADRENOTROPIC RECEPTORS
Raymond P. Ahlquist · American Journal of Physiology-Legacy Content · 1948 · 2.9K citations